Pharmacologic management of end-of-life delirium : translating evidence into practice

Article indépendant

HUI, David | CHENG, Shao-Yi | PAIVA, Carlos Eduardo

End-of-life delirium affects a vast majority of patients before death. It is highly distressing and often associated with restlessness or agitation. Unlike delirium in other settings, it is considered irreversible, and non-pharmacologic measures may be less feasible. The objective of this review is to provide an in-depth discussion of the clinical trials on delirium in the palliative care setting, with a particular focus on studies investigating pharmacologic interventions for end-of-life delirium. To date, only six randomized trials have examined pharmacologic options in palliative care populations, and only two have focused on end-of-life delirium. These studies suggest that neuroleptics and benzodiazepines may be beneficial for the control of the terminal restlessness or agitation associated with end-of-life delirium. However, existing studies have significant methodologic limitations. Further studies are needed to confirm these findings and examine novel therapeutic options to manage this distressing syndrome.

https://www.mdpi.com/2072-6694/16/11/2045

Voir la revue «Cancers, 16»

Autres numéros de la revue «Cancers»

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Gestion